Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 study
- Author(s)
- Papagiannis, A; Majjaj, S; Duhoux, FP; Agostinetto, E; Stanciu, AM; Vanhulst, T; Buisseret, L; Larsimont, D; Veys, I; Paesmans, M; Hammer, TB; Awada, A; Ameye, L; Rothe, F; Madriles, F; Cash, TP; Salgado, R; Willard-Gallo, K; Sotiriou, C; Vuylsteke, P; Neven, P; Ignatiadis, M;
- Journal Title
- Nature Communications
- Publication Type
- Online publication before print
- Abstract
- The NeoRHEA was a single-arm phase 2 study that included patients with estrogen receptor positive / human epidermal factor receptor 2 negative early breast cancer that received 4 cycles of neoadjuvant palbociclib and endocrine therapy. The primary outcome was baseline biomarkers of treatment resistance and secondary outcome was post-treatment transcriptional and epigenetic changes of tumor, immune and stromal cells. E2F targets and G2M checkpoint proliferation-related genes gene sets were enriched in baseline samples from resistant patients., Downregulation of E2F targets and G2M checkpoint post treatment was observed in tumor, endothelial and T cells. Gene Set Enrichment Analyses (GSEA) based on genes residing in the differentially accessible peaks revealed similar effects,. Moreover, decreases in CD8 + CD103+ tissue-resident memory cell marker genes were observed post-treatment and validated by multiplex immunohistochemistry. Our data reveal that treatment with palbociclib and endocrine therapy diminishes adaptive anti-tumor immunity by decreasing T cell proliferation and the presence of tissue-resident memory T cells NCT03065621.
- Department(s)
- Laboratory Research
- Publisher's Version
- https://doi.org/10.1038/s41467-025-66590-2
- Open Access at Publisher's Site
https://doi.org/10.1038/s41467-025-66590-2- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-12-05 02:49:46
Last Modified: 2025-12-05 02:55:47